Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose
The present disclosure relates to method for drying hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing polyethylene glycol, providing trehalose, mixing the hydrogel, the polyethylene glycol and the trehalose to obtain a mixture, and freeze drying the mixture to obtain a dried hydrogel comprising nanofibrillar cellulose. The present disclosure relates to a freeze-dryable hydrogel comprising nanofibrillar cellulose, to a freeze-dried hydrogel comprising nanofibrillar cellulose, and to a medical hydrogel comprising nanofibrillar cellulose and one or more therapeutic agent(s).
1. A freeze-dried medical aerogel comprising:
nanofibrillar cellulose,
a single active pharmaceutical ingredient selected from the group consisting of antibiotics, pain relievers; nicotine; opioids; nitroglycerin; scopolamine; clonidine; antidepressants; ADHD medication; vitamins; 5-hydroxytryptophan; Alzheimer's medication; acne medication; antipsoriatics, glucocorticoids; antiandrogens, antiestrogens, antimicrobial agents; anesthetics; analgesics; anti-inflammatory compounds or agents; antihistamines; beta-blockers; immunomodulators; and medication for treating diseases or disorders of skin,
polyethylene glycol, and
trehalose,
wherein the moisture content of the aerogel is 10% (w/w) or less, and
wherein the nanofibrillar cellulose, the polyethylene glycol and the trehalose are present in the aerogel in a weight ratio of nanofibrillar cellulose:polyethylene glycol:trehalose of 9-22:2-6:1.
2. The freeze-dried medical aerogel of claim 1 , wherein the content of the active pharmaceutical ingredient in the aerogel is in the range of 0.1-65% (w/w).
3. The freeze-dried medical aerogel of claim 1 , wherein the weight ratio of nanofibrillar cellulose:polyethylene glycol:trehalose is 9.5-20:2-4:1.
4. The freeze-dried medical aerogel of the claim 1 , wherein the nanofibrillar cellulose prior to incorporation into the aerogel provides a Brookfield viscosity of at least 2000 mPa·s, measured at 20° C±1° C., at a consistency of 0.8% (w/w) and at 10 rpm.
5. The freeze-dried medical aerogel of the claim 1 , wherein the nanofibrillar cellulose is selected from anionically modified nanofibrillar cellulose, cationically modified nanofibrillar cellulose and unmodified nanofibrillar cellulose, and TEMPO oxidized nanofibrillar cellulose.
6. The freeze-dried medical aerogel of claim 1 , wherein the active pharmaceutical ingredient is selected from metronidazole, nadolol, ketoprofen, lidocaine, fentanyl, buprenorphine, selegiline, methylphenidate, rivastigmine, hydrocortisone, bifluranol, cyoctol, cyproterone, delmadinone acetate, flutimide, nilutamide, oxendolone, ethamoxytriphetol, tamoxifen, and toremifene.
7. The freeze-dried medical aerogel of claim 1 , obtained with a method comprising:
comprising
providing a hydrogel comprising nanofibrillar cellulose,
providing polyethylene glycol,
providing trehalose,
mixing the hydrogel, the polyethylene glycol and the trehalose to obtain a mixture, and
freeze drying the mixture to obtain an aerogel comprising nanofibrillar cellulose.
8. The freeze-dried medical aerogel of claim 1 , wherein the nanofibrillar cellulose is the only polymeric gel-forming material in the aerogel.
9. The freeze-dried medical aerogel of claim 1 , wherein the nanofibrillar cellulose has a length exceeding 1 μm and a diameter smaller than 200 nm.
10. The freeze-dried medical aerogel of claim 1 , wherein the nanofibrillar cellulose has a number average diameter of a fibril in the range of 1-100 nm.
11. The freeze-dried medical aerogel of claim 1 , wherein the nanofibrillar cellulose prior to incorporation in the aerogel provides a zero shear viscosity in the range of 1000-100000 Pa·s and a yield stress in the range of 1-50 Pa, determined by rotational rheometer at a consistency of 0.5% (w/w) by weight in aqueous medium.